VANDA PHARMACEUTICALS (VNDA) News Headlines

▮ More

Date

Headline

12/19/2022 7:21:47 AM Vanda Pharma: Phase III Study Shows Potential Of Fanapt In Treating Bipolar I Disorder

12/19/2022 7:08:07 AM Vanda Pharma : Fanapt Shown To Be Effective In Bipolar I Disorder In Phase III Clinical Study

12/19/2022 7:00:00 AM Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study (Press Release)

12/2/2022 7:16:22 AM Vanda Pharma Says Phase II Study Of VQW-765 To Treat Anxiety Showed Lower Stress Levels

12/2/2022 7:01:22 AM Vanda Pharma Reports Results In Phase II Clinical Study Of VQW-765 In The Treatment Of Acute Performance Anxiety

8/4/2022 5:25:05 AM VNDA On Watch, NUVA Q2 Results Miss Estimates, MRTX Awaits FDA Decision...

2/4/2022 7:25:30 AM Vanda : Phase III Study Of Tradipitant In Gastroparesis Fails To Meet Prespecified Primary Endpoint

2/4/2022 7:00:00 AM Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis (Press Release)

1/14/2022 9:21:48 AM Vanda Settles HETLIOZ Patent Litigation With MSN

1/14/2022 8:38:37 AM Vanda Pharma Settles HETLIOZ Patent Litigation With MSN

8/3/2021 7:21:22 AM Vanda Closes Enrollment In ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients

4/6/2018 8:53:19 AM Jefferies Is Cutting VANDA PHARMACEUTICALS (VNDA) 2020 Estimate To 0.61 From 0.67

4/6/2018 8:53:03 AM Jefferies Is Lowering VANDA PHARMACEUTICALS (VNDA) 2019 Estimate To 0.83 From 0.92

4/6/2018 8:52:40 AM Jefferies Is Raising VANDA PHARMACEUTICALS (VNDA) 2018 Estimate To -0.83 From -0.92

4/6/2017 6:15:05 AM Jefferies Is Cutting VANDA PHARMACEUTICALS (VNDA) 2018 Estimate To -0.39 From -0.17

1/5/2017 6:24:33 AM Jefferies Is Increasing VANDA PHARMACEUTICALS (VNDA) 2017 Estimate To 0.03 From -0.04

1/5/2017 6:24:17 AM Jefferies Is Cutting VANDA PHARMACEUTICALS (VNDA) 2016 Estimate To -0.48 From -0.43

11/14/2013 4:52:12 PM Vanda Pharmaceuticals (VNDA) Is Rising Sharply On FDA Panel Recommendation

Older Articles